203 related articles for article (PubMed ID: 32015233)
21. Promyelocytic leukemia zinc finger and histone H1.5 differentially stain low- and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study.
Hechtman JF; Beasley MB; Kinoshita Y; Ko HM; Hao K; Burstein DE
Hum Pathol; 2013 Jul; 44(7):1400-5. PubMed ID: 23416030
[TBL] [Abstract][Full Text] [Related]
22. Carcinoids and high-grade neuroendocrine carcinomas of the ampulla of vater: a comparative analysis of 139 cases from the surveillance, epidemiology, and end results program-a population based study.
Albores-Saavedra J; Hart A; Chablé-Montero F; Henson DE
Arch Pathol Lab Med; 2010 Nov; 134(11):1692-6. PubMed ID: 21043824
[TBL] [Abstract][Full Text] [Related]
23. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.
Voortman J; Lee JH; Killian JK; Suuriniemi M; Wang Y; Lucchi M; Smith WI; Meltzer P; Wang Y; Giaccone G
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13040-5. PubMed ID: 20615970
[TBL] [Abstract][Full Text] [Related]
24. Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.
Pelosi G; Bianchi F; Dama E; Simbolo M; Mafficini A; Sonzogni A; Pilotto S; Harari S; Papotti M; Volante M; Fontanini G; Mastracci L; Albini A; Bria E; Calabrese F; Scarpa A
Virchows Arch; 2018 Apr; 472(4):567-577. PubMed ID: 29388013
[TBL] [Abstract][Full Text] [Related]
25. Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?
Sun TY; Hendifar A; Padda SK
Curr Oncol Rep; 2022 Jul; 24(7):819-824. PubMed ID: 35305210
[TBL] [Abstract][Full Text] [Related]
26. Molecular alterations of neuroendocrine tumours of the lung.
Rossi G; Bertero L; Marchiò C; Papotti M
Histopathology; 2018 Jan; 72(1):142-152. PubMed ID: 29239031
[TBL] [Abstract][Full Text] [Related]
27. Next-generation sequencing of salivary high-grade neuroendocrine carcinomas identifies alterations in RB1 and the mTOR pathway.
Goyal B; Duncavage EJ; Martinez D; Lewis JS; Chernock RD
Exp Mol Pathol; 2014 Dec; 97(3):572-8. PubMed ID: 25446844
[TBL] [Abstract][Full Text] [Related]
28. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract][Full Text] [Related]
29. Mutational analysis of pulmonary large cell neuroendocrine carcinoma: APC gene mutations identify a good prognostic factor.
Li M; Zhang Y; Zhou P; Miao Y; Li S; Jiang L
Lung Cancer; 2024 Jun; 192():107825. PubMed ID: 38795461
[TBL] [Abstract][Full Text] [Related]
30. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
Wu H; Yu Z; Liu Y; Guo L; Teng L; Guo L; Liang L; Wang J; Gao J; Li R; Yang L; Nie X; Su D; Liang Z
Cancer Commun (Lond); 2022 Dec; 42(12):1367-1386. PubMed ID: 36264285
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary carcinoid and related tumours.
Hasleton PS; Bostanci G
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():28-42. PubMed ID: 9337521
[TBL] [Abstract][Full Text] [Related]
32. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
[TBL] [Abstract][Full Text] [Related]
33. How phenotype guides management of the neuroendocrine carcinomas of the larynx.
López F; Hunt JL; Nixon IJ; Rinaldo A; Williams MD; Cardesa A; Ferlito A
J Laryngol Otol; 2018 Jul; 132(7):568-574. PubMed ID: 29909787
[TBL] [Abstract][Full Text] [Related]
34. [Genomics of neuroendocrine tumors of the lung and gastrointestinal tract: similarities and differences].
Tímár J; Patócs A
Magy Onkol; 2018 Jul; 62(2):77-82. PubMed ID: 30027934
[TBL] [Abstract][Full Text] [Related]
35. Clinical impact of mixed pulmonary carcinoma and carcinoid: the driver from their mono-clonal origin.
Graziano P; Parente P; Centra F; Milione M; Centonze G; Volante M; Cavazza A; Urbano D; Di Maggio G; Balsamo T; Di Micco C; Rossi G; Rossi A; Muscarella LA
Virchows Arch; 2024 Jan; 484(1):37-46. PubMed ID: 37773451
[TBL] [Abstract][Full Text] [Related]
36. Alterations in the expression of p53, KLF4, and p21 in neuroendocrine lung tumors.
Naranjo Gómez JM; Bernal JF; Arranz PG; Fernández SL; Roman JJ
Arch Pathol Lab Med; 2014 Jul; 138(7):936-42. PubMed ID: 24978920
[TBL] [Abstract][Full Text] [Related]
37. Gastric neuroendocrine neoplasms: tumour clonality and malignancy-associated large X-chromosomal deletions.
D'Adda T; Candidus S; Denk H; Bordi C; Höfler H
J Pathol; 1999 Nov; 189(3):394-401. PubMed ID: 10547602
[TBL] [Abstract][Full Text] [Related]
38. Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma: a multicentre study on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours of the Lung Working Group†.
Filosso PL; Rena O; Guerrera F; Moreno Casado P; Sagan D; Raveglia F; Brunelli A; Welter S; Gust L; Pompili C; Casadio C; Bora G; Alvarez A; Zaluska W; Baisi A; Roesel C; Thomas PA;
Eur J Cardiothorac Surg; 2015 Jul; 48(1):55-64. PubMed ID: 25406425
[TBL] [Abstract][Full Text] [Related]
39. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract][Full Text] [Related]
40. Proliferation Marker (Ki67) in Sub-Categorization of Neuroendocrine Tumours of the Lung.
Garg R; Bal A; DAS A; Singh N; Singh H
Turk Patoloji Derg; 2019; 35(1):15-21. PubMed ID: 30070306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
